Market CoverageARS Pharmaceuticals achieved significant commercial coverage for neffy, with 57% unrestricted coverage and a path towards over 80%.
Product DifferentiationNeffy stands out as the first approved needle-free epinephrine treatment, differentiating it from existing treatments like EpiPen.
Strategic PartnershipsThe expanded partnership with ALK Abelló is expected to strengthen US launch efforts for neffy by adding critical commercial resources and infrastructure.